Results showed that GSTZ1-OE decreased the expression levels of ferroptosis-related genes in sorafenib or erastin (an inducer of ferroptosis)-treated hepatoma cells, including GPX4, FTL, and SLC7A11. In contrast, GSTZ1-KO increased the levels of these above genes (Fig. 3E–G and Supplementary Fig. 1E, F). The gene discussed is SLC7A11; the disease is hepatocellular carcinoma.